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In acute promyelocytic leukemia (APL), normal retinoid signaling is disrupted by an abnormal 
PML-RARα fusion oncoprotein, leading to a block in cell differentiation. Therapeutic 
concentrations of all-trans-retinoic acid (ATRA) can restore retinoid-induced transcription and 
promote degradation of the PML-RARα protein. Autophagy is a catabolic pathway that utilizes 
lysosomal machinery to degrade intracellular material and facilitate cellular re-modelling. 
Recent studies have identified autophagy as an integral component of ATRA-induced myeloid 
differentiation.  
Methods 
As the molecular communication between retinoid signaling and the autophagy pathway is not 
defined, we performed RNA sequencing of NB4 APL cells treated with ATRA and examined 
autophagy-related transcripts.  
Results 
ATRA altered the expression of >80 known autophagy-related transcripts, including the key 
transcriptional regulator of autophagy and lysosomal biogenesis, TFEB (11.5-fold increase). 
Induction of TFEB and its transcriptional target, sequestosome 1 (SQSTM1, p62), is reduced in 
ATRA-resistant NB4R cells compared to NB4 cells. TFEB knockdown in NB4 cells alters the 
expression of transcriptional targets of TFEB and reduces CD11b transcript levels in response 
to ATRA.  
Conclusions 
We show for the first time that TFEB plays an important role in ATRA-induced autophagy 
during myeloid differentiation, and that autophagy induction potentiates leukemic cell 
differentiation. (Note: this study includes data obtained from NCT00195156, 
https://clinicaltrials.gov/show/NCT00195156). 
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Introduction 
Retinoids are signaling molecules related to Vitamin A (retinol) that have well-established roles 
in development and differentiation.1 Dietary retinoids are metabolized within cells to a bioactive 
form, all-trans-retinoic acid (ATRA), which exerts its effects by mediating gene transcription.1 
ATRA binds retinoic acid receptors (RARs) and rexinoid receptors (RXRs). These ligand-
dependent transcription factors form RXR-RAR heterodimers that preferentially bind to specific 
DNA sequence motifs, termed retinoic acid response elements (RAREs), in the promoters or 
enhancers of target genes.1 Through interactions with diverse, co-regulatory proteins the RXR-
RAR complexes regulate transcription.2 
Acute promyelocytic leukemia (APL), a distinct subtype of acute myeloid leukemia (AML), is 
defined by the clonal proliferation of granulocyte precursors halted at the promyelocyte stage 
of development.3 Cytogenetically, APL is distinguished by a chromosomal translocation 
affecting the RARα gene locus on chromosome 17q21 in malignant clones,4 most commonly 
generating the functional PML-RARα fusion oncogene.4 The PML-RARα oncoprotein binds to 
RAREs on retinoid target gene promoters. Because of its high affinity for co-repressor protein 
complexes, PML-RARα causes repressive epigenetic changes that inhibit the transcription of 
RARα target genes, many of which are involved in myeloid differentiation.5-7 While physiologic 
concentrations of ATRA (~1 nM) are unable to overcome this transcriptional repression, 
therapeutic concentrations (~1 μM) restore granulocytic differentiation in leukemic cells, 
allowing them to complete a finite life cycle.6 The incorporation of ATRA into clinical regimens 
has transformed outcomes for APL patients, with cure rates of >80% now observed.8 Recent 
data show that ATRA has a dual therapeutic effect on the PML-RARα oncoprotein: (i) it 
induces a conformational change in the oncoprotein that results in the dissociation of co-
repressor proteins and allows the preferential binding of transcriptional co-activators, and (ii) it 
promotes the degradation of the PML-RARα oncoprotein through co-operating proteolytic 
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mechanisms.4,9 This oncoprotein elimination, particularly in leukemia-initiating cells, results in 
sustained clinical responses.9 Recently, ATRA-induced differentiation has been shown to 
involve the induction of autophagy.10-13 
Autophagy is a constitutive pathway involved in the turnover of damaged or redundant 
proteins.14,15 The core machinery of autophagy is largely comprised of ‘AuTophaGy-related’ 
(ATG) proteins, which through a series of conjugation reactions are sequentially recruited to 
regulate autophagosome formation and fusion.16 While initially described as a non-specific 
degradation pathway, substrate selectivity in autophagy is achieved via adaptor proteins such 
as sequestosome1 (SQSTM1/p62) and NBR1.17,18 The regulation of autophagy is complex and 
occurs at cytoplasmic and transcriptional levels. The serine/threonine kinase mammalian 
target of rapamycin (mTOR) acts as a master cytoplasmic regulator of autophagy.18 Further 
cytoplasmic regulation is provided by adenosine monophosphate-activated protein kinase 
(AMPK) and myo-inositol-1,4,5-triphosphate (IP3) signaling.19 
The basic helix-loop-helix leucine zipper transcription factor EB (TFEB) promotes the 
transcription of a gene network that co-ordinates both autophagy and lysosomal 
biogenesis.20,21 Under basal conditions, TFEB is phosphorylated by mTOR and retained at the 
lysosome.22 Following autophagy activation TFEB is dephosphorylated and enters the nucleus 
to exert its transcriptional effects.21 Notable autophagy-related TFEB targets include LC3B, 
SQSTM1/p62, and ATG9B, a critical transmembrane protein in autophagosome membrane 
assembly.21 
It is known that ATRA induces autophagy in human APL cells.10-13 This ATRA-induced 
autophagy is important for the successful granulocytic differentiation of leukemic blasts.11,12,23 
Indeed, autophagy is likely involved in the degradation of the highly aggregate-prone PML-
RARα oncoprotein, a process dependent on the SQSTM1/p62 adaptor protein.12,13 However, 
as differentiation involves significant protein remodeling, autophagy may also drive leukemic 
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differentiation independently of oncoprotein elimination, as it has does in other hematopoietic 
cell types.4,11 Thus, the molecular communication between retinoid signaling pathways and 
autophagy remains poorly understood and is the focus of this study. 
Using genome-wide RNA sequencing technology, we examined the changes that occur in 
autophagy-related genes during ATRA-induced APL differentiation. We show for the first time 
that TFEB mRNA is strikingly increased by ATRA. Furthermore, shRNA-mediated knockdown 
of TFEB in APL cells impeded myeloid differentiation of leukemic cells. Collectively our data 
implicates TFEB as an important mediator of ATRA-induced differentiation in APL.   
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Materials and Methods 
Cell culture & drug treatments 
Cells were cultured as described in Faria et al.24 Valproic acid (1 mM, Sigma-P4543) and 
arsenic trioxide (0.5 μM, Sigma-A1010) were used. Brefeldin A (Sigma-B7651) was diluted 
from a 5 mg/ml stock in DMSO to a 10 uM working concentration. BFA was added 24 hours 
prior to analysis. All-trans-retinoic acid (ATRA) (Sigma-R2625) was diluted from a 1 mmol/L 
stock in 100% ethanol – to 1µM working concentration. The NB4 and ATRA-resistant NB4 
lines were described previously.24,25 
TFEB knockdown cell lines  
pLKO.1-puro shRNA vectors targeting TFEB (Sigma-TRCN0000437246 = shTFEB) or a 
scrambled off-target control (shScr) were transfected into HEK293T cells with lentiviral 
packaging plasmids pCMVΔ8.9 and pVSVG using Lipofectamine-2000 (Invitrogen-11668). 
NB4 cells were transduced with supernatant and media containing 20% serum in a 1:1 ratio. 
Cells then underwent a 10-day selection with puromycin (2 μg/mL) (Sigma-P7255). Two 
independent TFEB shRNA knockdown NB4 lines were used for some of the analyses shown. 
Primary human tissue  
Following local research ethics committee approval and informed consent, a pre-treatment 
bone marrow aspirate and peripheral blood samples were obtained from two patients newly 
diagnosed with APL. Whole samples were gradient-separated using Histopaque-1077 (Sigma-
10771), and a buffy coat of mononuclear cells, comprising predominantly a malignant 
promyelocyte population, was extracted. We also obtained RNA from peripheral blood 
mononuclear cells from solid tumor oncology patients treated with ATRA following the 
approved protocol as part of clinical trial NCT00195156.26 
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RNA extraction, cDNA synthesis, and quantitative real-time (qRT) PCR  











Gene expression amplicons were validated by sequencing. The transcript levels in biological 
replicates (n=6) were normalized to hPRT levels, and relative differences calculated.28 
Graphical displays and measurements of statistical significance were performed on GraphPad 
Prism software.  
RNA sequencing (RNA-seq) and analysis 
Total cellular RNA was extracted using an RNeasy mini-kit (Qiagen-74104) with on-column 
DNase treatment. For RNA sequencing, two independent biological replicates RNA samples 
were submitted to the Weill Cornell Genomics Core for quality checks, cDNA library 
preparation, and sequencing using the Illumina HiSeq-2000 platform. Raw sequence reads in 
fastq format were aligned to the HG19 genome using Tophat and differentially expressed 
genes based on calculated RPKM expression values were determined using the Galaxy 
(http://www.usegalaxy.org) implementation of Cufflinks/Cuffdiff using the Illumina iGenomes 
HG19 annotation.29 Unsupervised hierarchical clustering was performed and expression 
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heatmaps generated from sample RPKM values using Cluster and Treeview software 
(http://rana.lbl.gov/EisenSoftware.htm). Official gene symbols for transcripts were obtained 
using Gene ID (http://idconverter.bioinfo.cnio.es) and gene list comparisons were performed 
using Venny software (http://bioinfogp.cnb.csic.es/tools/venny/). Gene ontology analysis was 
performed using the Webgestalt server (http://www.webgestalt.org).30 Raw sequence reads 
are available in NCBI-GEO database under the accessions: GSE53258 and GSE53259.  
Creation of an autophagy/myeloid database 
A composite list of 522 autophagy-related human genes was generated from three publicly 
available autophagy databases: (i) the Human Autophagy Database (www.autophagy.lu), (ii) 
the Autophagy Database (http://autophagy.info/autophagy/list/GeneList) and (iii) the 
Autophagy Gene Ontology GO0006914 (www.amigo.geneontology.org) (Supplemental Table 
1A). We also generated a list of 217 genes associated with myeloid differentiation comprising 
known hematopoietic lineage markers such as ITGAM and key hematopoiesis-associated 
genes sourced from the GO:0030099 gene ontology (Supplemental Table 1B).  
ChIP sequencing analysis 
We accessed RARα and RNA polymerase II chromatin immunoprecipitation sequencing 
(ChIP-seq) data from ATRA-treated NB4 (GSE18886)7 and	 TSU-1621-MT (GSE60477)31 cells 
in WIG format (the summary output post alignment and MACS peak calling) from the NCBI-
GEO database. We visualized RARα and RNA polymerase II binding within the TFEB and 
p62/sqstm1 loci using Integrated Genome Viewer software 
(https://www.broadinstitute.org/igv/home). 
Western blotting 
Cellular protein extracts were lysed in modified RIPA buffer (50 mmol/L Tris–HCl, pH 7.4, 150 
mmol/L NaCl, 0.25% sodium deoxycholate, 1% IGEPAL, 1 mmol/L EDTA, 1x Pefabloc, 1x 
Protease inhibitor cocktail, 1 mmol/L Na3VO4, 1 mmol/L NaF). Protein samples were prepared 
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in NuPAGE LDS Sample buffer (NP008-Invitrogen), separated on NuPAGE 4%–12%, Bis–Tris 
gels (NP0322-Invitrogen) and electrophoretically transferred onto polyvinyl difluoride 
membranes (IB401001-Invitrogen). Membranes were incubated with anti-LC3A/B (MBL 
PD014) antibody diluted 1/1000 in 5% milk overnight, at 4˚C and with anti-β-actin (loading 
control) (Sigma-A5441) for one hour at room temperature. Proteins were visualized using 
relevant IR-DYE secondary antibodies (Li-Cor, Cambridge, UK) and quantified on the Odyssey 
IR imaging system (Li-Cor, Cambridge, UK). For all Western blots, integrated intensities are 
representative of three independent experiments.   
Flow cytometry assays 
Differentiation. CD11b live cells were incubated for 45 min with PE-conjugated anti-CD11b 
antibody (12-0118, eBioscience, UK) in 1% albumin/phosphate-buffered saline and washed 
with phosphate-buffered saline prior to analysis. An increase in surface expression of CD11b is 
detected as an increase in fluorescence in the PE channel.   
Autophagy. Cells were stained with the Cyto-ID autophagy detection kit (Enzo Life Sciences 
ENZ-51031-K200) according to the manufacturer’s instructions.  An increase in the number of 
autophagic vesicles is detected as an increase in fluorescence in the 488-2 channel. 
All data were collected on the BD LSR II flow cytometer with BD FACS Diva acquisition 




RNA sequencing of ATRA-treated APL cells confirms activation of a myeloid 
differentiation program 
We and others have recently shown that autophagy plays a role in the NB4 model of APL 
differentiation.11 To understand the transcriptional signaling pathways involved we used 
genome-wide RNA-seq to identify gene expression changes following exposure to therapeutic 
concentrations of ATRA (1 μM) for 72 hours. As has previously been shown, we 
morphologically confirmed that ATRA induces differentiation. Untreated NB4 cells have large 
round nuclei with minimal cytoplasm (Figure 1A). ATRA-treated cells display increased nuclear 
lobulation and a decreased nuclear to cytoplasmic (N:C) ratio characteristic of maturing 
granulocytes (Figure 1A). We next extracted RNA from control and ATRA-treated cells at 72 
hours and submitted samples from two independent biological repeats for complementary DNA 
(cDNA) library preparation and RNA sequencing. Differential gene expression analysis, 
calculated using Cuffdiff, identified 2,598 differentially expressed transcripts comprised of 
1,540 upregulated and 1,058 downregulated genes with a significant (q < 0.05) and greater 
than 2-fold change in mRNA expression following ATRA treatment (Supplemental Table 2A). 
Enrichment analysis showed that many differentially expressed genes grouped to gene 
ontologies comprising genes in the lysosome and immune response (Supplemental Table 2B).  
We examined the transcript changes of 217 genes involved in myeloid differentiation 
(Supplemental Table 2C). Cufflinks reads per kilobase of exon per million fragments mapped 
(RPKM) outputs from our duplicate samples were clustered using Cluster 3.0 software, and 
graphical outputs visualized as heatmaps using TreeView. A magnified section of our heatmap 
depicts a cluster of key myeloid genes, including CD11b/ITGAM, CEBPa, CEBPe, and GATA2, 
with similar patterns of expression (Figure 1B). Overall, we observed a >two-fold increase in 
the expression of 36 (bold print) and decreased expression of 12 (blue print) myeloid-
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differentiation genes (Supplemental Table 2C, bold print). Amongst the ATRA-upregulated 
genes were those encoding the critical myeloid transcription factors PU.1 (SP1 gene) and 
CEBPe (Figure 1B).32 The GATA2 transcription factor preserves a stem-like state in 
hematopoietic cells and is downregulated during differentiation.33 We found that ATRA-treated 
NB4 cells showed decreased GATA2 mRNA levels and we observed a similar decrease in 
transcripts for MYC, another transcription factor associated with an undifferentiated state 
(Figure 1B).34 We detected a decrease in the transcripts of CEBPa, a gene encoding a 
transcription factor involved in early myeloid differentiation but downregulated during the 
terminal phase of the process (Figure 1C).35 The mRNA levels of the ITGAM gene encoding 
CD11b, a frequently used surface marker of myeloid differentiation, were greatly increased 
(Figure 1B). This finding was validated by quantitative PCR of ITGAM transcripts in NB4 cells 
treated with ATRA or vehicle for 72 hours (Figure 1C). Further qPCR validation of mRNA 
changes in CEBPe, PIK3CD, GCSFR, CTSD, and the differentiation-associated autophagy 
maker, GABARAP11 confirmed their upregulation following ATRA (Figure 1C-H).  
RNA sequencing data indicates ATRA mediates autophagy gene transcription 
We examined ATRA-regulated expression changes in autophagy-related genes in NB4 cells 
by cross-referencing our autophagy gene list with those genes that displayed significant (q < 
0.05), >2-fold in mRNA levels in our RNA-seq. This identified 2,514 genes differentially 
expressed genes (DEGs) with ≥2-fold change following ATRA treatment in NB4 cells. Of the 
522 members of the composite autophagy-related genes, 84 were also differentially regulated 
in ATRA-treated NB4 cells (Supplemental Table 2D), consistent with reports linking autophagy 
and retinoid induced differentiation.11 Among the mRNAs increased was transcription factor EB 
(TFEB) (+11.5-fold change, q = 0.00022), a master transcriptional coordinator of autophagy 
and lysosomal biogenesis.36  
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To assess whether TFEB, a critical regulator of autophagy, is itself under direct retinoid 
receptor regulation we interrogated two independent, publicly available RARa AML ChIP-seq 
datasets (NCBI-GEO:GSE18886,GSE60477) that contain data on the genome-wide 
distribution of RARα and RNA polymerase II in NB4 and TSU-1621-MT AML cells treated with 
ATRA for 24 hours.7,31 RARa and RNA polymerase II bind to the TFEB locus in both NB4 and 
TSU-1621-MT AML cells, suggesting that RARa directly regulates TFEB expression in the 
presence of ATRA (Figure 2A). We confirmed an ATRA-mediated increase in TFEB mRNA in 
NB4 cells by qRT-PCR (Figure 2B). We detected a 15-fold induction of TFEB compared to 
untreated levels following 72 hours ATRA treatment (p < 0.0001). Furthermore SQSTM1/p62, 
a known transcriptional target of TFEB, was also induced by 6-fold (p < 0.0001) (Figure 
2B,i,ii).37 This was comparable to a 5.9-fold induction calculated by RNA-seq analysis 
(Supplemental Table 2A). Our RNA-seq showed an ATRA-induced, 2.1-fold increase in SIK3 
mRNA (Supplemental Table 2A), and we measured a comparable 2.5-fold induction by qPCR 
(p < 0.0001) (Figure 2B,iii).  
We then examined whether these genes were induced by ATRA in a differentiation-resistant 
derivative of NB4 APL cells, NB4R. We observed an ATRA-induction of TFEB, but to a lesser 
degree than that seen in the ATRA-sensitive NB4 cell line (2.5-fold increase) (Figure 2C,i). 
Similarly, the induction of SQSTM1/p62 and SIK3 was impaired in the differentiation-resistant 
line (Figure 2C,ii,iii), suggesting a role for these genes in leukemic cell differentiation.  
We then assessed whether elevation of these autophagy-associated genes could be detected 
in APL patient cells, treated ex-vivo with ATRA. Mononuclear cells separated from the bone 
marrow of a newly diagnosed APL patient were cultured ex-vivo +/- ATRA for 72 hours. TFEB, 
SQSTM1/p62, and SIK3 were induced to levels comparable to those in NB4 (Figure 2D,i-iii). 
This induction coincided with increased mRNA levels of CD11b and PIK3CD (Figure 2D,iv-v), 
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two genes induced during myeloid differentiation of APL cells (as in Figure 1C,E), confirming 
ex vivo differentiation of these primary patient leukemic cells.  
We also analyzed expression of these autophagy-associated genes in cDNA from peripheral 
blood mononuclear cells (PBMCs) isolated from patients with solid urological tumors that were 
treated with liposomal ATRA as part of a phase 1/2 clinical trial in 2007.38 We detected a 2-fold 
induction of TFEB by ATRA in PBMCs from this non-leukemic patient cohort (Supplemental 
Figure S1).  
shRNA-mediated depletion of TFEB impacts ATRA-mediated gene expression in NB4  
We then assessed the effects of shRNA-mediated depletion of TFEB on the expression of 
genes regulated by ATRA in NB4 cells. Cells lines expressing either shTFEB or a control-
targeting sequence in eGFP (shScr) were generated by a lentiviral-mediated transduction of 
NB4 cells. Successful TFEB depletion was confirmed by qRT-PCR. ATRA induced a 17-fold 
increase in TFEB mRNA in NB4 cells harboring a non-targeting shRNA, as compared to a 6.7-
fold ATRA-induction of TFEB in NB4 cells with a shRNA targeting TFEB (Figure 3A).  
These cell lines were then treated with ATRA or vehicle for 72 hours. RNA sequencing was 
performed, with two biological repeats, on: (i) vehicle-treated shScramble (shScr-Ctrl), (ii) 
ATRA-treated shScramble (shScr-ATRA), (iii) vehicle-treated TFEB-depleted (shTFEB-Ctrl) 
and (iv) ATRA-treated TFEB-depleted (shTFEB-ATRA). Cuffdiff analysis of our sequencing 
data from shScr-Ctrl versus shScr-ATRA identified 3,916 genes whose transcript levels were 
altered by ATRA by at least two-fold (q < 0.05, with RPKM > 0 in both conditions). Analysis of 
shTFEB-Ctrl versus shTFEB-ATRA identified 3,264 genes that were altered by ATRA in the 
TFEB-knockdown population (Supplemental Table 3A-B). Intersection of these two datasets 
highlighted 1,200 genes with altered expression in shScr but not in TFEB-depleted cells. 
Conversely, 548 genes were altered only in the shTFEB cells (Figure 3B, Supplemental Table 
3C). Another way to state these results is that the comparison of the shScr +/- ATRA provides 
 14 
the number of genes affected by ATRA, 3,916, and the comparison of the shScr +/- ATRA and 
the shTFEB + ATRA shows that 1,200 genes, a large number, are regulated by ATRA in the 
shScr but not in the shTFEB cells, and thus the expression of these 1,200 genes either directly 
or indirectly requires expression of TFEB and includes notable components of the autophagy 
pathway. 
TFEB regulates CLEAR network gene expression during ATRA-induced differentiation 
of APL cells 
TFEB is a master regulator of a gene network that controls both autophagy and lysosomal 
biogenesis, known as the Coordinated Lysosomal Expression and Regulation (CLEAR) 
network.39 This includes a network of 471 genes reported to be direct transcriptional targets of 
TFEB.21 We examined TFEB expression and the TFEB-regulated CLEAR genes in our data-
set, comparing vehicle and ATRA-treated shScr and shTFEB cells (Supplemental Table 4A). 
Using hierarchical clustering we visualized expression of a subset of CLEAR-network genes in 
ATRA-treated shScr and ATRA-treated shTFEB cells (Figure 3C). This analysis of the gene 
cluster, which included TFEB, identified a sub-cluster of genes, including TFEB, GABARAP, 
and p62/SQSTM1. That expression of p62/SQSTM1, GABARAP, and TFEB clusters together 
is significant and suggests potential co-regulation of these genes (Figure 3D). We identified a 
panel of genes that, like TFEB, shows impaired ATRA-induced expression in TFEB-depleted 
NB4 cells. The effect of TFEB depletion on ATRA regulation of the key autophagy genes, 
p62/SQSTM1, GABARAP, and ATG16L1, was confirmed by qRT-PCR (Figure 3D,E,F). The 
ATRA-mediated induction of p62/SQSTM1 was attenuated in TFEB-knockdown cells, 
consistent with p62/SQSTM1 being a direct TFEB target (Figure 3). p62/SQSTM1 has a 
functional role in ATRA-mediated NB4 differentiation.12 Other known ATRA-regulated 
autophagy genes include granulin, GRN, a gene encoding a glycoprotein with a role in 
inflammation that is highly expressed in myeloid cells (Figure 3C, highlighted).40  
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TFEB depletion reduces ATRA-mediated myeloid differentiation of APL cells 
We next evaluated whether TFEB expression was required for ATRA-induced expression of 
the myeloid differentiation signature in APL cells by comparing vehicle and ATRA-treated 
control and TFEB-depleted cells (Supplemental Table 4B). Cufflinks RPKM values for these 
genes in shScr-Ctrl, shScr-ATRA, shTFEB-Ctrl, and shTFEB-ATRA cells were visualized using 
Treeview heatmaps (Figure 4A-B, Supplemental Table 4B). From our panel of 217 myeloid 
genes we identified clustered sub-networks of genes, suggesting potential co-regulation, that 
displayed ≥1.5-fold increases in transcript levels during ATRA treatment of non-transfected 
NB4 cells (Supplemental Table 2C). We used a 1.5-fold change cutoff for Figure 4A-B to 
detect statistically significant changes in myeloid gene expression related to ATRA and TFEB. 
We detected genes increased by ATRA, such as ITGAM, ETS1, CEBPE, and TFE3 (Figure 
4A), and genes decreased by ATRA, including MYC, GATA2, and CEBPA (Figure 4B). ATRA 
induced a ~40-fold increase in ITGAM/CD11b expression in shScr cells as compared to ~10-
fold induction in shTFEB cells (Figure 4A and Supplemental Table 4B). We next tested 
whether this transcriptional phenotype that suggested impaired myeloid differentiation following 
depletion of TFEB expression was also evident by assessing the morphology of cells following 
ATRA treatment. ATRA-treated shScr cells at 48 hours displayed early morphologic signs of 
granulocyte differentiation (Figure 4C, upper panels). ATRA-treated shTFEB cells showed 
reduced differentiation, with a persistent immature phenotype (Figure 4C, lower panels, 
arrows).  
We also validated expression of these differentiation markers, ITGAM/CD11b, GCSFR, and 
CTSD, by qRT-PCR. ATRA-treated shTFEB cells displayed less induction of each of these 
transcripts at 72 hours compared to ATRA-treated shScr cells (p < 0.0001) (Figure 4D,E,F). 
Similarly, ATRA induced a 9-fold increase in CEBPe transcripts in shScr cells as compared to 
a ~6.5-fold increase in shTFEB cells (Figure 4A, Supplemental Table 4B). Conversely, the 
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ATRA-associated reduction in GATA2 was greater in shScr (-10-fold) compared to the shTFEB 
cells (-5.8-fold) (Figure 4B, Supplemental Table 4B).33 Depletion of TFEB also impaired ATRA-
induced reduction of transcripts for transcription factors CEBPa and MYC (Figure 4B). We also 
noted lack of induction of ETS1, a transcription factor with documented roles in hematopoiesis, 
in the NB4 shTFEB cells (Figure 4A).41 
Surface expression of ITGAM/CD11b protein was also examined by flow cytometry 
(Supplemental Figure S2). ATRA-induced differentiation is significantly reduced in the shTFEB 
cells compared to shScr controls (p < 0.0001). 
These results show for the first time a major, functional role for TFEB in ATRA-induced 
myeloid differentiation-utilising gene, cell and morphological analysis in cell lines and primary 
patient samples. Importantly, the effects of TFEB knockdown on the expression of several 
myeloid differentiation genes are striking, placing these genes downstream of TFEB.  
Effect of TFEB knockdown on autophagy 
Our data thus far has suggested that ATRA-induced TFEB plays an important role in leukemic 
cell differentiation. We next evaluated whether the effects of TFEB were related to its 
regulation of autophagy. To do this, we initially compared autophagic flux in the shScr and 
shTFEB clones. Autophagic flux refers to the entire autophagy process, from sequestration to 
degradation. Autophagosome accumulation or an increase in autophagy markers may be a 
consequence of either increased autophagy initiation or a block in autophagosome turnover. 
Therefore, to differentiate between induction of autophagosomes and failure of turnover, cells 
were pre-treated with chloroquine to block lysosome function and autophagosome turnover. 
Any autophagosome accumulation beyond that observed with chloroquine alone is then 
attributed to enhanced autophagy initiation. 
We examined the expression levels of LC3 I/II (autophagosome marker) in ATRA-treated cells, 
in the absence and presence of chloroquine (Figure 5). Analysis of LC3 II by Western blot 
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indicates increased LC3 II in the untreated shTFEB cells (lane 5) compared with shScr controls 
(lane 1), indicative of enhanced endogenous autophagy – despite TFEB silencing. This 
enhancement of endogenous autophagy is further evident in the presence of chloroquine (lane 
3 versus lane 7), which blocks turnover of the endogenous autophagosomes. In the presence 
of ATRA alone, LC3 II levels were increased to a similar extent in both the scramble control 
and shTFEB cells, when compared to their own untreated controls. In the scramble control 
cells this ATRA-induced increase was further enhanced by chloroquine, indicative of 
autophagy flux. However no increase in flux was observed in the shTFEB clone (lanes 7 & 8). 
The levels of LC3 II in the combination-treated shTFEB cells are no greater than those 
observed with chloroquine alone. This is indicative of less initiation of autophagy by ATRA in 
the shTFEB clone. 
Evidence for alternative autophagy 
The previous LC3II blot indicated higher basal levels of LC3 II protein in the shTFEB clone 
(Figure 5). Therefore, despite TFEB knockdown there are still autophagosomes present, which 
also accumulate when the cells are treated with chloroquine. TFEB is only one of several 
transcription factors known to influence autophagy and alternative mechanisms of autophagy 
have been described, which do not need all of the components of autophagy initiation 
complexes. We therefore investigated whether there might be a TFEB independent / 
alternative autophagy present in these cells. One of these pathways is thought to originate at 
the Golgi and is disrupted by Brefeldin A (BFA), a golgi inhibitor.42 We therefore examined 
whether BFA sensitive-autophagy might contribute to the autophagy present during 
differentiation.  
For these experiments, we employed an additional marker of autophagy, Cyto-ID. This is a 
fluorescent dye which accumulates inside autophagosomes and enables the quantitation of 
autophagosomes by flow cytometry. We initially examined the effects of BFA on endogenous 
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levels of autophagy in the shScr and shTFEB clones. TFEB knockdown alone significantly 
increased Cyto-ID fluorescence, (black overlay) beyond scramble control (grey filled 
histogram) (*** p = 0.0009 internal bar graph), consistent with the enhanced levels of 
autophagosomes in the shTFEB clone noted in Figure 5. In addition, treatment of both 
scramble control (red overlay) (** p = 0.0073) and shTFEB (pink overlay) (*** p = 0.0001) cells 
with BFA inhibited endogenous autophagy to levels below untreated scramble controls (Figure 
6A,i). Triplicate data are presented as mean fluorescence intensities, with each control 
normalised to one (Figure 6A,ii). These data suggest that the elevation of basal autophagy in 
the shTFEB cells is primarily due to BFA-sensitive/alternative autophagy. 
To assess if ATRA-induced autophagy is also influenced by BFA we treated shScr and 
shTFEB cells with ATRA in the absence and presence of BFA (Figure 6B). In both the 
scramble control (i) and shTFEB (ii) cells the ATRA-induced increase in autophagosomes (red 
overlays) is significantly reduced in the presence of BFA (blue overlays) (*** p < 0.0001). In the 
shTFEB cells fluorescence levels are reduced to levels below those detected in untreated 
cells. These data were combined as triplicate mean fluorescence intensities, with each control 
normalized to one (Figure 6B,iii), highlighting the inhibitory effect that TFEB silencing has on 
ATRA-induced autophagy, an effect which is augmented by BFA treatment. Western blot 
analysis confirmed ATRA-mediated induction of autophagy/LC3II, in both the scramble and 
shTFEB clones, with lower levels of LC3 II induced in the shTFEB clone relative to its control. 
BFA reduced the levels of LC3 II in both, however it did not eliminate LC3 II accumulation in 
either (Figure 6C).  
Effect of BFA on differentiation of shScr and shTFEB cells 
To assess the involvement of BFA-dependent autophagy in differentiation we examined the 
effect of BFA on CD11b expression. As shown in Supplemental Figure S3 (i) BFA treatment 
reduced endogenous differentiation in both the shScr (red overlay) (*** p = 0.0007) and 
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shTFEB (pink overlay) (* p = 0.010) cells. (ii) Triplicate mean fluorescence intensities highlight 
the BFA-dependent inhibition of endogenous differentiation in both scramble and shTFEB 
cells. In addition, as shown in Supplemental Figure S4, ATRA-induced differentiation in the 
shScr (i) and shTFEB (ii) cells (red overlays) is significantly reduced by BFA (blue overlays) 
(*** p < 0.0001 and p = 0.0004, respectively). Triplicate data were combined as mean 
fluorescence intensities, with each control normalised to one (Supplemental Figure S4,iii). 
These data again highlight the effect of TFEB silencing on ATRA-induced differentiation, an 
effect that is further enhanced by BFA treatment.  In this experiment we cannot distinguish 
between a reduction in surface CD11b due to inhibition of alternative autophagy or due to 
impaired Golgi trafficking. Future studies may wish to address this as soon as more selective 




We and others have reported that ATRA induces autophagy in APL cells and that this 
autophagy contributes to granulocytic differentiation.11-13,23 The mechanisms through which 
ATRA activates autophagy, however, have not been well characterized. Autophagy is mTOR-
dependent, as mTOR inhibition with rapamycin increases autophagy and promotes PML-RAR 
degradation.13 PU.1 binds at the promoter of the microtubule-associated protein 1S (MAP1S) 
gene, a positive regulator of autophagy, and MAP1S inhibition interferes with APL cell 
differentiation.43 As PU.1 expression is suppressed in APL and restored by therapeutic levels 
of ATRA, this is a potential indirect mechanism of autophagy induction.44 ATRA may also have 
a role in autophagosome maturation through redistribution of a cation-dependent mannose-6-
phosphate receptor to the developing autophagosome, leading to vesicle acidification.45 
Building on our previous work, we assessed the transcriptional effects of ATRA on autophagy-
related genes (Supplemental Table 3B). We found altered transcript levels of >80 autophagy-
related genes following ATRA addition, opening avenues for further study of the crosstalk 
between retinoid signaling and autophagy. From this gene list we focused on the master 
autophagy regulator TFEB as a potential critical communicator between retinoid signaling and 
autophagy. Although previous studies have used microarray technology (e.g. GSE19201) to 
assess gene expression changes in APL cells following ATRA treatment, this is the first study 
to use unbiased, genome-wide approaches to examine the role of TFEB in ATRA-induced 
differentiation. 
Two independent, published ChIP-seq analyses7,31 show RARa and RNApol II recruitment to 
the TFEB locus, indicating that TFEB may be a direct retinoid receptor target (Figure 2A). We 
show that TFEB expression increases in NB4 cells treated with ATRA (Figure 2B). We also 
show TFEB induction in cultured primary human APL cells and in non-myeloid primary cells 
treated with ATRA (Figure 2D). TFEB expression is induced in murine hepatocytes by 
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overexpression of cyclic AMP response element–binding protein (CREB) and its partner, 
CRTC2.46 Analysis of published liver ChIP-seq data showed CREB binding peaks within the 
TFEB gene locus46,47 ATRA induces the activity of CRE-dependent transcription factors, 
offering a possible mechanism for secondary TFEB activation upon ATRA treatment.48 
Studies of TFEB regulation to date have focused on post-translational modifications to the 
TFEB protein. Under normal cellular conditions TFEB is phosphorylated by mammalian target 
of rapamycin complex 1 (mTORC1), resulting in its binding with 14-3-3 proteins and 
sequestration in the cytoplasmic compartment.22,49 Supporting the idea that mTORC1 is the 
primary regulator of the TFEB protein, nutrient deprivation leads to nuclear translocation of 
TFEB and increased expression of TFEB target genes.49 Delineation of the cellular localization 
of the TFEB protein during ATRA-mediated APL cell differentiation is an area for further 
investigation. Functional depletion of TFEB in NB4 also impaired ATRA induction of the key 
autophagy associated genes p62/SQSTM1, GABARAP, and ATG16L1 (Figure 3D,E,F). Our 
data suggest that TFEB is a key mediator of ATRA-induced autophagy processes during 
myeloid differentiation. 
The large fold increase in TFEB mRNA during ATRA-mediated APL differentiation, along with 
our data that this induction is attenuated in differentiation-resistant NB4R cells (Figure 2C), led 
us to test for a functional role of TFEB in the APL cell differentiation process. Gene expression 
profiling by RNA-seq of shTFEB NB4 cells revealed a failure of these cells to activate the 
myeloid transcription program upon ATRA treatment, with impaired reductions in GATA2, 
CEBPα and MYC transcripts, as well as impaired induction of PU.1 and CEBPE. Transcripts of 
ITGAM (CD11b), a commonly reported marker of myeloid differentiation, were also induced by 
ATRA to a lesser extent in shTFEB cells (Figure 4D). Similarly, ATRA induction of GCSFR and 
CTSD transcripts is impaired in TFEB-depleted NB4 cells. Our data convincingly show for the 
first time a major role for TFEB in the ATRA-mediated myeloid differentiation of APL cells.  
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One major function of TFEB is the coordination of autophagic flux by transcriptional regulation 
of the CLEAR network of genes encoding the machinery involved in autophagosome 
formation, cargo recognition, vacuolar fusion, and lysosomal degradation. Indeed, we confirm 
that TFEB knockdown alters the expression of downstream CLEAR network genes (Figure 3). 
As a protein degradation pathway, autophagy has been implicated in the degradation of the 
aggregate-prone PML-RARα oncoprotein, a process necessary for sustained therapeutic 
remissions in APL.9,12,13 We previously showed that promoting autophagy can potentiate 
ATRA-mediated differentiation of the HL60-Diff-R cell line, a human AML line which does not 
harbor the PML-RARα oncoprotein and does not differentiate in response to ATRA treatment 
alone.11 This finding suggests that autophagy plays a role in the cellular remodeling that occurs 
during differentiation and is not solely involved in oncoprotein elimination. Thus, TFEB 
induction may be critical in managing the considerable proteostatic stress of a differentiating 
cell.  
Our analysis of LC3 II expression and autophagosome accumulation indicates an impairment 
in autophagic flux in shTFEB cells. This impairment in autophagy may be a key factor in the 
impairment of differentiation in shTFEB cells. The importance of autophagy in these cells is 
underscored by the fact that shTFEB cells can utilize an additional TFEB-independent pathway 
that can be inhibited by brefeldin A. This pathway is not just upregulated as a compensation in 
the shTFEB cells – it is also present in the shScr control cells – suggesting co-existence of 
autophagy pathways. This alternative pathway has previously been described in the context of 
leukemia cells. Wang et al. reported an alternative autophagic mechanism, in canonical 
autophagy-defective leukemia cells (Atg7-deleted K562 cells) – which was reversed by 
brefeldin A.50  
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This is the first study to indicate a potential role for alternative autophagy in differentiation.  It is 
imperative to better understand the contribution of various autophagy pathways in order to 
effectively modulate it for the purposes of enhancing differentiation. 
It is important to acknowledge that TFEB is a transcription factor that targets E-box (CANNTG) 
sequences on DNA and regulates the transcription of genes outside the CLEAR network. 
TFEB downstream-target genes involved in diverse cellular processes, including inflammation, 
metabolism and cell death, have been reported.39 The effects of TFEB on differentiation could 
also be mediated by these genes, and indeed, a wider range of TFEB target genes may be 
identified in different cell contexts. 
In conclusion, this study explores the communication between retinoid signaling and 
autophagy during APL cell differentiation. We identify TFEB, a master transcriptional regulator 
of autophagy and lysosomal biogenesis, as a direct retinoid target that is induced during 
ATRA-mediated differentiation. Importantly, we show that TFEB and autophagy, play a critical 
role in the myeloid differentiation process. Induction of TFEB may be of therapeutic benefit in 
broadening the use of differentiation therapy in ATRA-resistant, acute leukemias. The prospect 
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Figure 1. APL cells treated with ATRA activate a myeloid differentiation program. NB4 
cells were seeded at 0.2 x 105 cells/mL and treated with either 1 μM ATRA or vehicle control 
for 72 hours. (A) Light microscopic morphological examination of control cells (upper panel) 
shows cells with large round nuclei and minimal cytoplasm consistent with an undifferentiated 
state (40x magnification). ATRA-treated cells (lower panel) show increased nuclear lobulation 
and decreased nuclear:cytoplasmic ratio indicative of granulocytic differentiation (40x 
magnification). (B) Gene expression changes induced by ATRA were examined using RNA 
sequencing (n=2). Shown here are the expression changes in a subset of genes associated 
with myeloid differentiation. All genes shown have a greater than 2-fold change in expression. 
Genes were grouped using Cluster software and a heatmap was generated with Treeview 
software. Critical myeloid transcription factors and markers of differentiation are highlighted. 
(D-H) Quantitative PCR validation of RNA sequencing data was performed. Measurements of 
CD11b, C/EBPɛ, PIK3CD, GCSFR, CTSD and the differentiation-associated autophagy gene, 
GABARAP mRNA levels are shown in ATRA-treated NB4 cells. Values are given as n-fold 
induction compared to untreated cells and normalized to housekeeping gene hPRT (n=6). t-
test, **** p < 0.0001. 
 
Figure 2. Effects of ATRA treatment on autophagy-related genes. (A) We interrogated a 
publicly available ChiP-seq datasets to examine retinoid signaling at the TFEB locus. An 
integrated genome viewer (IGV) depiction is shown of RARα and RNA-polymerase II (polII) 
binding at the TFEB gene following 24 hours after ATRA treatment in NB4 (grey) and TSU-
1621-MT (black) cells. (B) (i-iii) NB4 cells were seeded at 0.2 x 105 cells/mL and treated with 
either 1μM ATRA or vehicle control. RNA was harvested at 72 hours. Measurement of TFEB, 
p62 and SIK3 mRNA levels by qPCR is shown (n=6). (C) (i-iii) Measurement of TFEB, p62 and 
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SIK3 mRNA levels in differentiation-resistant NB4R cells seeded at 0.2 x 105 cells/mL and 
treated with 1μM ATRA for 72 hours (n=6). (D) (i-v) Mononuclear cells extracted from the bone 
marrow of a patient with APL were treated with ATRA in methylcellulose culture for 72 hours 
prior to RNA harvest. qPCR measurement of TFEB, p62, SIK3, CD11b and PIK3CD mRNA 
levels is shown (n=1). For all qPCR experiments, values are given as n-fold induction 
compared to untreated cells and normalized to housekeeping gene hPRT. Statistical 
significance determined with t-test, * p < 0.05, **** p < 0.0001. 
 
Figure 3. Effects of TFEB knockdown on genes of the CLEAR network during APL cell 
differentiation. NB4 cells expressing non-targeting shRNA (shScr) or shRNA targeting TFEB 
(shTFEB) were seeded at 0.2 x 105 cells/mL and treated with either 1 μM ATRA or vehicle 
control. RNA was extracted at 72 hours. (A) Quantification of TFEB mRNA levels by qRT-PCR 
as validation of TFEB knockdown efficiency. We show that shTFEB impairs ATRA induction of 
TFEB. (B) RNA was sequenced in duplicate (n=2). Gene expression changes in shScr- and 
shTFEB-NB4 cells treated with ATRA were determined using Cuffdiff software. The Venn 
diagram depicts the cross-referencing of genes differentially expressed between ATRA-treated 
shScramble cells (yellow circle) and ATRA-treated shTFEB cells (purple circle). Genes outside 
the intersection are those affected by TFEB depletion. (C) A subset of genes from the CLEAR 
network with a greater than 1.5-fold change in expression following ATRA treatment underwent 
cluster analysis and are depicted here using a Treeview heatmap (legend provided). 
Quantification of SQSTMI/p62 (D), GABARAP (E) and ATG16L1 (F) mRNA levels by qRT-
PCR. For all qPCR, values are given as n-fold induction compared to untreated cells and 
normalised to housekeeping gene hPRT (n=6). Statistical analysis was performed using 
ANOVA with Bonferroni’s post hoc test, *** p < 0.001, **** p < 0.0001. 
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Figure 4. Effects of TFEB knockdown on ATRA-mediated APL cell differentiation. Using 
RNA sequencing, the expression of genes involved in myeloid differentiation was examined in 
NB4 cells expressing either non-targeting shRNA (shScr) or shRNA targeting TFEB (shTFEB) 
treated with ATRA for 72 hours (n=2). (A) Genes induced by ATRA are displayed following 
cluster analysis using Treeview software (legend provided). Only genes that display a greater 
than 1.5-fold change in expression in wild type NB4 cells are shown. Highlighted genes 
represent important myeloid transcription factors and markers of differentiation normally 
activated during differentiation but whose expression is reduced by TFEB depletion. (B) Genes 
whose expression is reduced by ATRA are shown. Highlighted genes represent important 
transcription factors that fail to be appropriately downregulated in shTFEB cells. (C) 
Quantification of CD11b mRNA levels by qPCR in shSCR and shTFEB cells following 72 hours 
of ATRA treatment. Values are given as n-fold induction compared to untreated cells and 
normalized to housekeeping gene hPRT (n=6). t-test, **** p < 0.0001. (D) Morphologic 
appearance of shSCR (upper panels) and shTFEB (lower panels) following 72 hours of ATRA 
treatment under light microscopy (40x magnification). Arrows depict persistent undifferentiated 
cells in TFEB-depleted cells.   
 
Figure 5 ATRA-induced autophagy flux is impeded by TFEB knockdown. NB4 cells 
expressing non-targeting shRNA (shScr) or shRNA targeting TFEB (shTFEB) were seeded at 
0.5 x 105 cells/mL. Cells were treated with ATRA alone (1 µM) for 72 hours, chloroquine alone 
(10 µM) for 72 hours or a combination of both, with chloroquine added 2 hours prior to the 
addition of ATRA. (i) Autophagic flux was assessed by Western blot analysis of LC3 II levels in 
shScr (lanes 1-4) or shTFEB cells (lanes 5-8), following treatment with ATRA (lanes 2 and 6), 
chloroquine (lanes 3 and 7) or a combination of both (lanes 4 and 8). An increase in LC3 II in 
scramble control cells treated with ATRA and chloroquine, beyond chloroquine alone is 
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indicative of flux. In the shTFEB clone however, flux is impeded – with no induction in LC3 II 
beyond that induced with chloroquine alone. (ii) All bands were quantified and normalised to β-
actin. These data are presented as integrated intensities, with all bands normalised to 
untreated shScr cells (n=2). 
 
Figure 6 Brefeldin A (BFA) inhibited endogenous and ATRA-induced autophagy in 
scramble control and TFEB knockdown cells. NB4 cells expressing non-targeting shRNA 
(shScr) or shRNA targeting TFEB (shTFEB) were seeded at 0.5 x 105 cells/mL. (A) (i) To 
confirm the effects of TFEB knockdown on endogenous autophagy, the Cyto-ID autophagy 
detection assay was used to measure autophagosome formation in shTFEB (black overlay) 
and shScr (grey histogram) cells. To assess the effects of BFA on endogenous levels of 
autophagy, cells were treated with BFA (10µM) for 24 hours – which reduced autophagy levels 
in both the shScr (red overlay) and shTFEB (pink overlay) cells. (ii) Data from three 
independent experiments is presented to the right as mean fluorescence intensities ± SEM 
with each control normalised to one (*** p < 0.001, ** p < 0.01). (B) The effect of BFA on 
ATRA-induced autophagy was assessed in (i) shScr and (ii) shTFEB cells. Cells were treated 
with ATRA (1 µM) for 72 hours, with BFA (10µM) added for the final 24 hours. BFA significantly 
reduced ATRA-induced autophagy (blue overlay) in both scramble control and shTFEB cells, 
when compared to ATRA alone (red overlays) – with a greater reduction in the shTFEB cells. 
Data from three independent experiments is presented as mean fluorescence intensities ± 
SEM within each panel (*** p < 0.0001). (iii) These data are combined and presented as 
triplicate mean fluorescence intensities, with each control normalised to one. (C) Autophagy 
was also assessed by Western blot analysis of LC3 II levels in shScr (lanes 1-4) or shTFEB 
cells (lanes 5-8), following treatment with ATRA alone (lanes 2 and 6), BFA alone (lanes 3 and 
7) or a combination of both (lanes 4 and 8). An increase in LC3 II in ATRA-treated scramble 
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control and shTFEB cells was significantly reduced by BFA (lanes 4 & 8), yet not eliminated. 
All bands were quantified and normalised to β-actin. These data are presented as integrated 
intensities, with each band normalised to untreated shScr cells (n=2).  
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Supplemental Figure S1.	Peripheral blood mononuclear cells (PBMCs) were obtained 
from patients with non-hematologic malignancy undergoing investigative in vivo ATRA 
therapy. qRT-PCR measurements of TFEB mRNA levels were performed on stored 
complementary DNA from these samples. Values are given as n-fold induction compared to 
untreated cells and normalized to housekeeping gene hPRT (n=3). Mann Whitney U test. ***p 
< 0.001. 
 
Supplemental Figure S2. TFEB knockdown impedes ATRA-induced differentiation in 
NB4 cells. NB4 cells expressing non-targeting shRNA (shScr) or shRNA targeting TFEB 
(shTFEB) were seeded at 0.5 x 105 cells/mL and treated with either 1 µM ATRA or vehicle 
control for 72 hours. (i) Surface expression of CD11b was used to assess differentiation in 
untreated shScr (grey histogram), untreated shTFEB cells (black overlay) and in ATRA treated 
shScr (red overlay) and shTFEB (pink overlay) cells. (ii) Data from three independent 
experiments is presented to the right as mean fluorescence intensities ± SEM with each 
control normalised to one (*** p < 0.0001).  
 
Supplemental Figure S3. Inhibition of Brefeldin A (BFA)-dependent autophagy reduced 
endogenous differentiation in scramble control and TFEB knockdown cells. NB4 cells 
expressing non-targeting shRNA (shScr) or shRNA targeting TFEB (shTFEB) were seeded at 
0.5 x 105 cells/mL and treated with 10 µM BFA or vehicle control for 24 hours. (i) Surface 
CD11b expression was assessed. Basal levels of differentiation are elevated in the shTFEB 
cells (black overlay) when compared to scramble control (grey histogram). BFA reduced 
endogenous differentiation in both shScr (red overlay) and shTFEB (pink overlay) cells. (ii) 
Data from three independent experiments is presented to the right as mean fluorescence 
intensities ± SEM (*** p < 0.001 * p < 0.01).  
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Supplemental Figure S4. Inhibition of Brefeldin A (BFA)-dependent autophagy reduced 
ATRA-induced differentiation in scramble control and TFEB knockdown cells. NB4 cells 
expressing non-targeting shRNA (shScr) or shRNA targeting TFEB (shTFEB) were seeded at 
0.5 x 105 cells/mL and treated with ATRA (1 µM) for 72 hours, with BFA (10 µM) added for the 
final 24 hours. Differentiation was assessed at day 3 by measurement of surface CD11b 
expression (n = 3). ATRA-induced differentiation (red overlays) was significantly reduced by 
BFA (blue overlays) in both the (i) shScr and (ii) shTFEB cells. Data from three independent 
experiments is presented as mean fluorescence intensities ± SEM within each panel (*** p < 
0.0005). (iii) These data are combined and presented as triplicate mean fluorescence 
intensities, with each control normalised to one.  
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Supplemental Table 1 
Lists of autophagy (A) and myeloid (B) genes examined. 
 
Supplemental Table 2 
A. Differential genes identified in vehicle and ATRA-treated NB4 cells. 
B. Gene ontologies identified from differential expressed genes in ATRA-treated NB4 cells. 
C. Expression of myeloid genes in ATRA-treated NB4 cells. 
D. Comparison of expression of autophagy and ATRA-regulated myeloid-related genes in 
ATRA-treated NB4 cells. 
 
Supplemental Table 3 
A. ATRA-induced differential gene expression in NB4 cells transduced with non-gene 
targeting shRNA (shControl). 
B. ATRA-induced differential gene expression in NB4 cells transduced with shRNA 
targeting TFEB (shTFEB).  
C. Identification of ATRA-regulated TFEB target genes in NB4 cells. 
 
Supplemental Table 4 
A. Effect of TFEB depletion on ATRA regulation of the CLEAR network expression. 
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